Diclofenac-potassium in migraine

Drugs

Volumn 57, Issue 6, 1999, Pages 991-1003

  McNeely, Wendy ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; DICLOFENAC; DICLOFENAC POTASSIUM; ERGOTAMINE; IBUPROFEN; PROSTAGLANDIN; SUMATRIPTAN;

ABDOMINAL PAIN; ANKLE SPRAIN; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; EDEMA; FATIGUE; HEADACHE; HEPATITIS; HUMAN; JAUNDICE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOPHOBIA; PROSTAGLANDIN SYNTHESIS; SOMNOLENCE; TABLET; TACHYCARDIA; TOOTH PAIN; VOMITING; WORK CAPACITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; DICLOFENAC; HUMANS; MIGRAINE DISORDERS; NAUSEA; VOMITING;

EID: 0033011299     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957060-00016     Document Type: Article

References (40)

1. 1. Baumel B. Migraine: a pharmacological review with newer options and delivery modalities. Neurology 1994 May; 44 Suppl. 3; 13-7
2. 2. Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc 1996 Nov; 71: 1055-66
3. 3. Pryse-Phillips WEM. Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Can Med Assoc J 1997 May 1; 156: 1273-87
4. 4. Goadsby PJ, Olesen J. Diagnosis and management of migraine. BMJ 1996 May 18; 312: 1279-83
5. 5. Saper JR. Diagnosis and symptomatic treatment of migraine. Headache 1997; 37 Suppl. 1: S1-14
6. 6. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 19-28
7. 7. Blau JN. Migraine: therories of pathogenesis. Lancet 1992 May 16; 339: 1202-7
8. 8. Solomon GD. Therapeutic advances in migraine. J Clin Pharmacol 1993; 33 (3): 200-9
9. 9. Senard JM, Montastruc JL. Recent advances in the pharmacology of antimigraine drugs. Drugs Today 1992; 28 (2): 131-43
10. 10. Todd PA, Sorkin EM. Diclotenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988; 35: 244-85
11. 11. Diclofenac, oral. Prescribing information. 1998 PDR Generics, 4th ed, Montvale, New Jersey: 866-70
12. 12. Edson KJ, Ezzet N, Integrated summary of efficacy: GP 45 840 12, Cataflam tablets, diclofenac-K. Novartis Pharma AG (Basel), 1995 Sep. (Data on file)
13. 13. Diclofenac. 1998 AHFS Drug Information, American Hospital Formulary Service; 1597-1603
14. 14. Bakshi R, Jacobs LD, Lehnert S, et al. A double-blind, placebo-controlled trial comparing the analgesic efficacy of two formulations of diclofenac in postoperative dental pain. Curr Ther Res 1992; 52 (3): 435-42
15. 15. Olson NZ, Sunshine A, Zighelbolm I, et al. Onset and duration of analgesia of diclofenac potassium in the treatment of postepisiotomy pain. Am J Ther 1997; 4: 239-46
16. 16. Bauduin H, Famaey J-P. Comparison of the analgesic effects of β-cyclodextrin-piroxicam, sodium naproxen, and potassium diclofenac utilising the dental pain model. J Pharm Care Pain Symptom Control 1995; 3 (2): 19-29
17. 17. Adair SF, Nelson SL, Brahim JS, et al. Dose-ranging study measuring the analgesic efficacy of diclofenac potassium [abstract no. PII-61]. Clin Pharmacol Ther 1990; 47 (2): 163
18. 18. Moran M. Double-blind comparison of diclofenac potassium, ibuprofen and placebo in the treatment of ankle sprains. J Int Med Res 1991; 19: 121-30
19. 19. Bahamonde LA, Saavedra H. Comparison of the analgesic and anti-inflammatory effects of diclofenac potassium versus piroxicam versus placebo in ankle sprain patients. J Int Med Res 1990; 18: 104-11
20. 20. Moran M. An observer-blind comparison of diclofenac potassium, piroxicam and placebo in the treatment of ankle sprain. Curr Med Res Opin 1990; 12 (4): 268-74
21. 21. Dahlöf C, Björkman R. Diclofenac-K (50 and 100mg) and placebo in the acute treatment of migraine. Cephalalgia 1993 Apr; 13: 117-23
22. 22. Cortelli P, Pierangeli G, Corsmi R, et al. Pain control in migraine attacks: results from a double-blind, randomized, within-patient, placebo-controlled trial comparing diclofenac-K and ergotamine + caffeine [abstract]. Cephalalgia 1996 Aug; 16: 359
23. 23. Diclofenac K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a non-steroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriplan and placebo. Cephatalgia 1999; 19: 1-9. In press
24. 24. Diclofenac-K/Cafergot Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a non-steroidal anti-inflammatory drug, diclofenac-potassium, in comparison to cafergot and placebo. Novartis Pharma AG (Basel). 604man2.doc/final draft; 1998 (Data on file)
25. 25. Pilgrim AJ. The clinical prolle of sumatriplan: efficacy in migraine. Eur Neurol 1994; 34 Suppl. 2: 26-34
26. 26. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for the controlled trials of drugs in migraine. First edition. Cephalalgia 1991; 11: 1-12
27. 27. Rainsford KD. Diclofenac (voltaren: voltarol)-associated hepatotoxicity. Inflammopharmacology 1994; 2: 333-6
28. 28. Sallie RW, McKenzie T, Reed WD, et al. Diclofenac hepatitis, Aust N Z J Med 1991; 21: 251-5
29. 29. Diclofenac-potassium prescribing information. Novartis Pharma AG (Data on file)
30. 30. Lipton RB, Stewart WF, Von Korff M. The burden of migraine; a review of cost to society. Pharmacoeconomics 1994 Sep; 6: 215-21
31. 31. Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997 Mar; 48 Suppl. 3: S4-9
32. 32. Solomon GD, Price KL. Burden of migraine; a review of its socioeconomic impact. Pharmacoeconomics 1997; 11 Suppl. 1: 1-10
33. 33. Solomon GD, Litaker DG. The impact of drug therapy on quality of life in headache and migraine. Pharmacoeconomics 1997 Apr; 11: 334-42
34. 34. Von Seggern RL, Adelman JU. Cost considerations in headache treatment. Part 2. Acute migraine treatment. Headache 1996; 36 (8): 493-502
35. 35. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomies 1998 Jun; 13: 667-76
36. 36. Gilkey SJ, Ramadan NM. Use of over-the-counter drugs in migraine: issues in self-medication. CNS Drugs 1996 Aug; 6: 83-9
37. 37. Karachalios GN, Fotiadou A, Chrisikos N, et al. Treatment of acute migraine attack with diclofenac sodium: a double-blind study. Headache 1992 Feb; 32: 98-100
38. 38. Hering R, Couturier EGM, Steiner TJ. Intramuscular diclofenac in late treatment of migraine [letter]. Cephalalgia 1996 Oct; 16: 453
39. 39. Goa KL, Balfour JA. Management of acute migraine attacks: defining the role of sumatriptan. Dis Manage Health Outcomes 1997 Sep; 2: 141-55
40. 40. Sumatriptan. Prescribing information. 1998 PDR Generics, 4th edition; Montvale, New Jersey; 2564-72